A phase 3, multicenter, randomised, double-blind, placebo-controlled, parallel group, efficacy and safety trial of bapineuzumab (AAB-001, ELN115727) in subjects with mild to moderate Alzheimer's disease who are apolipoprotein Ee4 non-carriers.
100 Clinical Results associated with Janssen Alzheimer Immunotherapy (Holding) Ltd.
0 Patents (Medical) associated with Janssen Alzheimer Immunotherapy (Holding) Ltd.
100 Deals associated with Janssen Alzheimer Immunotherapy (Holding) Ltd.
100 Translational Medicine associated with Janssen Alzheimer Immunotherapy (Holding) Ltd.